Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program. As of the latest announcement, the company has repurchased a total of 1,641,514 ordinary fully paid securities, with an additional 9,177 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its research and development of treatments aimed at addressing unmet medical needs in the neurology sector.
YTD Price Performance: -11.60%
Average Trading Volume: 720
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.01B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.